Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PCI-32765
Drug: Rifampin

First Posted Date: 2013-01-08

Last Posted Date: 2013-04-17

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT01763021

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: Ketoconazole
Drug: Rifampicin

First Posted Date: 2013-01-04

Last Posted Date: 2014-05-26

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 16

Registration Number: NCT01760642

Locations: 🇰🇷
Seoul National Universtiy Hospital, Seoul, Korea, Republic of

Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection

Phase 2

Conditions: Hip Prosthetic Joint Infection

Interventions: Drug: VANCOMYCIN
Drug: CEFTRIAXONE
Drug: LINEZOLID
Drug: CLINDAMYCIN
Drug: SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)
Drug: FLUOROQUINOLONE
Drug: RIFAMPIN

First Posted Date: 2012-12-28

Last Posted Date: 2014-05-28

Lead Sponsor: University Hospital, Tours

Target Recruit Count: 100

Registration Number: NCT01757236

Locations: 🇫🇷
CHRU de Tours, Tours, Indre et Loire, France
🇮🇹
Azienda Opedaliera Universitaria San Maria della Misericordia, Udine, Italy
🇫🇷
CHU de Nantes, Nantes, France

and more 6 locations

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

Phase 2

Terminated

Conditions: Prosthetic Joint Infections of Knee
Infected Spacers
Prosthetic Joint Infections of Hip

Interventions: Drug: CEM-102
Drug: IV or Oral standard of care antibiotics
Drug: Rifampin

First Posted Date: 2012-12-28

Last Posted Date: 2019-04-19

Lead Sponsor: Arrevus Inc.

Target Recruit Count: 14

Registration Number: NCT01756924

The Effect of PXR Activation on Blood Pressure Regulation

Phase 4

Completed

Conditions: Blood Pressure Regulation

Interventions: Drug: Placebo
Drug: Rifampicin

First Posted Date: 2012-09-21

Last Posted Date: 2014-12-30

Lead Sponsor: University of Oulu

Target Recruit Count: 22

Registration Number: NCT01690104

Locations: 🇫🇮
Oulu University Hospital, Oulu, Finland

A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: aleglitazar
Drug: rifampicin

First Posted Date: 2012-09-06

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT01679639

A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Abiraterone acetate
Drug: Rifampicin

First Posted Date: 2012-08-01

Last Posted Date: 2013-01-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 19

Registration Number: NCT01655147

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tasimelteon
Drug: Rifampin
Drug: Ketoconazole

First Posted Date: 2012-07-11

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01637636

Locations: 🇺🇸
QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Probenecid
Drug: Empagliflozin (BI 10773)
Drug: Empagliflozin
Drug: Rifampicin

First Posted Date: 2012-07-06

Last Posted Date: 2014-07-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT01634100

Locations: 🇩🇪
1245.83.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

Phase 2

Terminated

Conditions: HIV Infection
Tuberculosis

Interventions: Drug: Standard-dose Lopinavir/Ritonavir
Drug: Double-dose Lopinavir/Ritonavir
Drug: Raltegravir
Drug: Isoniazid
Drug: Pyridoxine
Drug: Pyrazinamide
Drug: Ethambutol
Drug: Rifampin
Drug: Rifabutin

First Posted Date: 2012-05-18

Last Posted Date: 2018-02-13

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 71

Registration Number: NCT01601626

Locations: 🇵🇪
Asociacion Civil Impacta Salud y Educacion - Miraf CRS (11301), Lima, Peru
🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇭🇹
Les Centres GHESKIO CRS (30022), Port-au-Prince, Haiti

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy